NADAC acquisition cost data for AMLODIPINE BESYLATE 5 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| Generic Name | amlodipine besylate and valsartan |
| Brand Name | Exforge |
| Manufacturer | Novartis Pharmaceuticals Corporation |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Pharmacologic Class | Angiotensin 2 Receptor Blocker |
| Product Type | HUMAN PRESCRIPTION DRUG |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 68180075109 | $0.0112 | 2022-01-19 | Rx |
| 00904637061 | $0.0104 | 2022-12-21 | Rx |
| 29300024205 | $0.0104 | 2022-12-21 | Rx |
| 29300024210 | $0.0104 | 2022-12-21 | Rx |
| 29300024219 | $0.0104 | 2022-12-21 | Rx |
| 29300039705 | $0.0104 | 2022-12-21 | Rx |
| 29300039710 | $0.0104 | 2022-12-21 | Rx |
| 29300039719 | $0.0104 | 2022-12-21 | Rx |
| 33342001510 | $0.0104 | 2022-12-21 | Rx |
| 42806005605 | $0.0104 | 2022-12-21 | Rx |
Generic: Amlodipine Besylate/Valsartan | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $4.6M | 7,974 | 1,580 | $10.63 |
| 2020 | $4.2M | 6,903 | 1,352 | $10.65 |
| 2021 | $3.4M | 5,283 | 1,080 | $10.85 |
| 2022 | $2.5M | 3,704 | 871 | $10.80 |
| 2023 | $2.4M | 3,063 | 648 | $12.40 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $420.7K | 532 | 109 |
| California | $265.1K | 365 | 72 |
| New Jersey | $245.9K | 309 | 65 |
| Florida | $243.1K | 325 | 70 |
| Texas | $145.4K | 212 | 43 |
| Pennsylvania | $100.3K | 124 | 27 |
| Maryland | $96.6K | 101 | 28 |
| North Carolina | $91.9K | 92 | 25 |
| Puerto Rico | $63.1K | 125 | 17 |
| South Carolina | $55.8K | 66 | 17 |
| Georgia | $55.6K | 60 | 17 |
| Connecticut | $51.6K | 61 | 15 |
| Ohio | $46.6K | 69 | 15 |
| Kentucky | $46.0K | 49 | N/A |
| Illinois | $45.4K | 60 | 12 |
| Virginia | $42.1K | 45 | N/A |
| Arizona | $41.7K | 53 | 12 |
| Michigan | $32.1K | 43 | N/A |
| Missouri | $30.5K | 35 | N/A |
| Tennessee | $27.7K | 34 | N/A |
| Alabama | $25.1K | 32 | N/A |
| Louisiana | $20.1K | 34 | N/A |
| Indiana | $18.6K | 25 | N/A |
| Hawaii | $18.6K | 20 | N/A |
| Massachusetts | $17.5K | 14 | N/A |
| Wisconsin | $17.5K | 28 | N/A |
| West Virginia | $13.8K | 13 | N/A |
| Iowa | $13.7K | 16 | N/A |
| Montana | $13.2K | 12 | N/A |
| Arkansas | $12.7K | 20 | N/A |
| Delaware | $11.0K | 17 | N/A |
| Washington | $7.7K | 15 | N/A |
| Nebraska | $5.8K | 13 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.